4/A: TOI CFO Amends Stock Sale for Tax Liabilities

The Oncology Institute's CFO, Robert Ross Carter, filed an amended Form 4 to correct details of a stock sale made to cover tax liabilities from an RSU award.

Summary

• Robert Ross Carter, Chief Financial Officer of The Oncology Institute, Inc. (TOI), filed an amended Form 4.
• The amendment corrects the transaction code, the number of shares sold, and the sale price as reflected in the original filing made on January 5, 2026.
• The transaction involved the disposition of 244 shares of common stock on January 2, 2026.
• The shares were sold at a price of $3.67 per share.
• This sale was executed to cover tax liabilities arising from the vesting of an RSU award on January 1, 2026.
• Following this reported transaction, Carter beneficially owns 235,125 shares of common stock.

Sentiment

Score: 5

Explanation: The filing is a routine amendment to an insider transaction disclosure, correcting minor details of a sale made for tax purposes. It does not contain information that would significantly alter the company's outlook or financial health, thus maintaining a neutral sentiment.

Industry Context

This filing is a routine disclosure of an insider transaction and does not provide information related to broader industry trends or competitive landscape within the oncology sector.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine, small-scale insider transaction for tax purposes and not indicative of a change in management's confidence or company fundamentals.

Key Dates

Keywords

The Oncology Institute, TOI, Form 4, Insider Transaction, Stock Sale, RSU, Tax Liabilities, Robert Ross Carter, CFO